Welbert Gomes Rocha

Welbert Gomes Rocha

Auto-generated profile, based on publicly available information

Welbert Gomes Rocha

Genetic Basis of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Escola Paulista de Medicina, Universidade Federal de São Paulo 1

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2025 in European Thyroid Journal
Verified
Journal Article
Open access
DTDebora Mota Dias Thomaz
Debora Mota Dias Thomaz
WRWelbert Gomes Rocha
Welbert Gomes Rocha
JAJulia Cavallari Albuquerque
Julia Cavallari Albuquerque
AVAline de Oliveira Ribeiro Viana
Aline de Oliveira Ribeiro Viana
JVJulia Maranhão Fagundes Velloni
Julia Maranhão Fagundes Velloni
JCJanete Cerutti
Janete Cerutti
Objective: This proof-of-concept, cross-sectional study assessed the feasibility and clinical relevance of detecting circulating tumor DNA (ctDNA) and RNA (ctRNA) in plasma of patients with thyroid cancer. The analysis was performed concurrently with clinical and biochemical assessment to explore its value as a complementary tool for postoperative surveillance. Methods: Thirty-four patients whose primary tumors had been molecularly profiled for key driver mutations and gene fusions were enrolled. Using a tumor-informed strategy, digital PCR assays were designed to detect patient-specific alterations in matched plasma ctDNA and ctRNA collected between 2021 and 2023. Molecular findings were correlated with treatment response categories according to the 2015 American Thyroid Association (ATA) guidelines. Results: ctDNA and/or ctRNA were detected in all patients with a structurally incomplete response, showing full concordance with imaging findings. In contrast, 91% of patients with an excellent response had undetectable ctDNA/ctRNA, consistent with remission. Among those with indeterminate and biochemical incomplete response group, results were variable: one patient with undetectable Tg exhibited an ETV6::NTRK3 fusion in cfRNA, while two of three with biochemical incomplete response tested negative for ctDNA/ctRNA. Conclusion: This cross-sectional analysis demonstrated that liquid biopsy accurately reflected disease activity and showed strong concordance with primary tumor alterations. These findings support its feasibility and clinical potential as an adjunct to conventional monitoring, particularly when Tg measurement or tumor tissue availability is limited. Prospective longitudinal studies are warranted to validate its role in personalized postoperative surveillance of thyroid cancer.

1 January 2026 in Endocrine Oncology
Verified
Journal Article
Open access
LSLuiza Sisdelli
Luiza Sisdelli
WRWelbert Gomes Rocha
Welbert Gomes Rocha
DTDébora Mota Dias Thomaz
Débora Mota Dias Thomaz
RHRoxane Hatanaka
Roxane Hatanaka
RSRenata Elen Costa da Silva
Renata Elen Costa da Silva
JCJanete Cerutti
Janete Cerutti
The AGK::BRAF fusion is a recurrent oncogenic alteration in sporadic pediatric papillary thyroid carcinoma (PTC), frequently associated with multifocal disease and pulmonary metastasis. However, the molecular and cellular consequences of AGK::BRAF expression in thyroid follicular cells remain poorly defined. Here, we investigated the biological effects of AGK::BRAF in PCCL3 thyroid cells and compared them with those induced by clinically established pediatric PTC oncogenic drivers, including RET/PTC1, RET/PTC3, ETV6::NTRK3, BRAF V600E, and wild-type BRAF. AGK::BRAF-expressing cells exhibited the most robust MAPK/ERK activation, characterized by markedly enhanced ERK and MEK phosphorylation relative to all other oncogenic drivers analyzed. By contrast, STAT3 and AKT signaling remained comparatively modest and did not show consistent oncogene-specific activation patterns. Functionally, AGK::BRAF expression induced features of thyroid dedifferentiation, including reduced sodium–iodide symporter (NIS) expression and impaired iodide uptake. Concomitantly, AGK::BRAF-expressing cells exhibited increased frequencies of micronuclei and chromatin bridges, together with disruption of three-dimensional telomere architecture, including reduced telomere signal number and intensity, altered spatial organization, and increased nuclear volume. Three-dimensional structured illumination microscopy (3D-SIM) further demonstrated chromatin remodeling, characterized by increased chromatin condensation accompanied by enlarged interchromatin spaces. Collectively, these findings suggest that AGK::BRAF is a dominant oncogenic driver of sustained MAPK/ERK signaling coupled to thyroid dedifferentiation, nuclear architectural remodeling, telomere dysfunction, and genomic instability. These coordinated molecular and structural alterations provide a mechanistic basis for the aggressive clinical course observed in AGK::BRAF-driven pediatric PTC.